Novo Nordisk has officially announced the availability of Wegovy® (semaglutide 2.4 mg) in Malaysia, marking a significant milestone in the country’s fight against obesity and its related health complications.
The launch comes at a critical time, as recent findings from the National Health and Morbidity Survey (NHMS) 2023 reveal that nearly 54.4% of Malaysian adults are living with overweight or obesity — a growing public health challenge that demands comprehensive and sustainable solutions.
Obesity is increasingly recognised as a chronic and complex disease, associated with more than 200 potential health complications, including type 2 diabetes, cardiovascular disease, hypertension and dyslipidaemia.
Beyond its physical impact, obesity can significantly affect quality of life, mental wellbeing and long-term health outcomes, reinforcing the need for evidence-based medical interventions alongside lifestyle changes.
A Science-Based Approach to Weight Management
Wegovy® is a once-weekly injectable medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for adults living with obesity or overweight who present with at least one weight-related comorbidity.
The treatment is suitable for individuals with a Body Mass Index (BMI) of ≥30 kg/m², or ≥27 kg/m² in the presence of conditions such as prediabetes, type 2 diabetes, hypertension, obstructive sleep apnoea or cardiovascular disease.
The medication works by mimicking GLP-1 (glucagon-like peptide-1), a naturally occurring hormone released by the gut after meals. By targeting areas of the brain that regulate appetite and food intake, Wegovy® helps reduce hunger, control cravings and support sustained weight loss.
Clinical evidence has shown that Wegovy® can deliver weight loss of 20% or more in people living with obesity, while preserving lean body mass and promoting healthier fat reduction.
Redefining Obesity Care in Malaysia
Dr. Praful Chakkarwar, General Manager of Novo Nordisk Malaysia, described the launch as a pivotal step in transforming obesity care locally. He emphasised that Wegovy® is part of a broader, long-term commitment that goes beyond medication, encompassing local clinical research, corporate collaborations, community education initiatives and public awareness platforms such as Truth About Weight.
According to Dr. Chakkarwar, addressing obesity requires a shift in mindset — from viewing it as a lifestyle failure to recognising it as a medical condition that deserves structured, compassionate and science-led care.
Breaking Stigma and Encouraging Holistic Care
Professor Dr. Rohana Abdul Ghani, Consultant Endocrinologist and President of the Malaysian Obesity Society (MYOS), highlighted that obesity is influenced by a combination of biological, behavioural and environmental factors.
She stressed that misconceptions surrounding obesity often lead to stigma, self-blame and emotional distress, creating additional barriers to effective weight management.
By integrating medical therapy with education, empathy and multidisciplinary care, healthcare providers can help individuals build resilience, reduce stigma and achieve more sustainable health outcomes.
Emeritus Professor Dr. Chan Siew Pheng further reinforced the importance of a multidisciplinary approach, involving physicians, nutritionists, nurse educators, physiotherapists and mental health professionals.
She noted that metabolic adaptations following weight loss often contribute to weight regain, underscoring the need for long-term medical support rather than short-term solutions.
Protecting Heart Health Through Obesity Management
The link between obesity and cardiovascular disease remains a key concern. Dato’ Sri Dr. Azhari Rosman, Senior Consultant Cardiologist, highlighted that effective obesity management plays a crucial role in reducing cardiovascular risks and improving overall health outcomes.
Addressing excess weight early can help prevent long-term complications and reduce the burden on Malaysia’s healthcare system.
With the introduction of Wegovy®, Novo Nordisk Malaysia continues to demonstrate its commitment to improving the lives of people living with chronic conditions. As obesity rates continue to rise, the availability of innovative, clinically proven treatments offers renewed hope for patients and healthcare providers alike.
By combining medication, education, lifestyle support and multidisciplinary care, Malaysia takes a meaningful step toward a healthier future — one where obesity is managed with understanding, science and compassion rather than stigma.
Keywords :
- Wegovy Malaysia
- Novo Nordisk Malaysia
- obesity treatment Malaysia
- semaglutide 2.4mg
- weight loss medication Malaysia
- obesity and cardiovascular risk
- GLP-1 obesity treatment
- Malaysian obesity statistics
- Wegovy weight loss
- obesity management Malaysia
